Work

Abstract 5319: Circulating tumor DNA (ctDNA)-based profiling of acquired resistance to the fibroblast growth factor receptor (FGFR)2/3 inhibitor lavengratinib(ABSK061) in patient(pt)s with advanced solid tumors.

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-5319

Authors: Yue Wang, Chunyu Zhou, Liyun Zhao, Chaoze Cheng, Zhixuan Zhu, Zishuo Wang, Peng Zhang, Jing Zhang, Hua Zou, Jing Ji, Hongping Yu, Ji Zhu, Yan Zhao, Dewei Li, Yongsheng Li, Wei Li, Yanru Qin, Shujun Yang, Nannan Zhang

Institutions: Abbisko Therapeutics Co., Ltd. (China), Zhejiang Cancer Hospital, Liaoning Cancer Hospital & Institute, Chongqing University, Chongqing Cancer Hospital, First Hospital of Jilin University, First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148640843

Cites:

Cited by:

Related to: